Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study is looking at the efficacy, durability, safety, and tolerability of multiple
single doses of Ketamine vs. active placebo for treating patients with treatment resistant
depression who are taking an antidepressant that is not working for them.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Baylor College of Medicine Icahn School of Medicine at Mount Sinai National Institute of Mental Health (NIMH) Stanford University University of Texas Yale University